Abstract
In their role as molecular chaperones, heat shock proteins serve as central integrators of protein homeostasis within cells. As part of this function, they guide the folding, assembly, intracellular disposition and proteolytic turnover of many key regulators of cell growth, differentiation and survival. Not surprisingly then, heat shock proteins are over expressed in many types of cancer, and induction of the stress response may actually be required for cells to tolerate the genetic disarray characteristic of malignant transformation. Regulation of heat shock protein levels via the stress response is complex, but recent data indicate that the molecular chaperone Hsp90 plays a key role. Specifically, Hsp90 inhibitors alter the multi-chaperone complexes associated with Heat Shock Factor 1 (HSF1), the dominant transcription factor controlling induction of the stress response, and stimulate HSF1-activated heat shock gene expression. Induction of this heat shock response has now emerged as an important consideration in the further clinical development of Hsp90 inhibitors for several reasons. First, tumors in which the stress response is compromised appear particularly sensitive to Hsp90 inhibition. Second, induction of the stress response by Hsp90 inhibitors provides a sensitive pharmacodynamic endpoint with which to monitor drug action in individual patients. Third, Hsp90 inhibitors display important therapeutic interactions with both conventional DNA-targeted chemotherapeutics and newer molecularly targeted agents. These interactions are, at least in part, due to modulation of the stress response by these drugs. Lastly, stress response induction by Hsp90 inhibitors may have therapeutic benefits in non-neoplastic disorders such as heart disease, stroke and neurodegenerative diseases. These benefits are just beginning to be explored.
Keywords: Hsp90, multi-chaperone, pharmacodynamic, heat shock gene
Current Cancer Drug Targets
Title: The Stress Response: Implications for the Clinical Development of Hsp90 Inhibitors
Volume: 3 Issue: 5
Author(s): Luke Whitesell, Rochelle Bagatell and Ryan Falsey
Affiliation:
Keywords: Hsp90, multi-chaperone, pharmacodynamic, heat shock gene
Abstract: In their role as molecular chaperones, heat shock proteins serve as central integrators of protein homeostasis within cells. As part of this function, they guide the folding, assembly, intracellular disposition and proteolytic turnover of many key regulators of cell growth, differentiation and survival. Not surprisingly then, heat shock proteins are over expressed in many types of cancer, and induction of the stress response may actually be required for cells to tolerate the genetic disarray characteristic of malignant transformation. Regulation of heat shock protein levels via the stress response is complex, but recent data indicate that the molecular chaperone Hsp90 plays a key role. Specifically, Hsp90 inhibitors alter the multi-chaperone complexes associated with Heat Shock Factor 1 (HSF1), the dominant transcription factor controlling induction of the stress response, and stimulate HSF1-activated heat shock gene expression. Induction of this heat shock response has now emerged as an important consideration in the further clinical development of Hsp90 inhibitors for several reasons. First, tumors in which the stress response is compromised appear particularly sensitive to Hsp90 inhibition. Second, induction of the stress response by Hsp90 inhibitors provides a sensitive pharmacodynamic endpoint with which to monitor drug action in individual patients. Third, Hsp90 inhibitors display important therapeutic interactions with both conventional DNA-targeted chemotherapeutics and newer molecularly targeted agents. These interactions are, at least in part, due to modulation of the stress response by these drugs. Lastly, stress response induction by Hsp90 inhibitors may have therapeutic benefits in non-neoplastic disorders such as heart disease, stroke and neurodegenerative diseases. These benefits are just beginning to be explored.
Export Options
About this article
Cite this article as:
Whitesell Luke, Bagatell Rochelle and Falsey Ryan, The Stress Response: Implications for the Clinical Development of Hsp90 Inhibitors, Current Cancer Drug Targets 2003; 3 (5) . https://dx.doi.org/10.2174/1568009033481787
DOI https://dx.doi.org/10.2174/1568009033481787 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Prevention of Sudden Cardiac Death in Hemodialysis Patients
Cardiovascular & Hematological Disorders-Drug Targets High-Density Lipoprotein Quantity or Quality for Cardiovascular Prevention?
Current Pharmaceutical Design Hydrogen Sulfide Regulates Vascular Inflammation and its Related Signaling Pathways
Current Signal Transduction Therapy Correlation of Urine Biomarkers: Microalbuminuria and Spot Urine Protein among Diabetic Patients. Application of Spot Urine Protein in Diabetic Kidney Disease, Nephropathy, Proteinuria Estimation, Diagnosing and Monitoring
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Highest Mortality During the Last Year Before and the First Year After Start of Dialysis Treatment in Type 2 Diabetic Patients with Nephropathy
Current Diabetes Reviews Roles of Mitogen-Activated Protein Kinases in the Regulation of CYP Genes
Current Drug Metabolism Pre-Clinical and Clinical Evaluation of Nuclear Tracers for the Molecular Imaging of Vulnerable Atherosclerosis: An Overview
Current Medicinal Chemistry Editorial [Hot Topic: Pharmacogenomics: Achievements, Challenges and Prospects, for Patients, Pharmaceutical Industries and Healthcare Systems (Guest Editor: Despina Sanoudou)]
Current Pharmaceutical Design Probiotics as Biotherapeutic Agents: Present Knowledge and Future Prospects
Current Pharmaceutical Design The Use of Dexmedetomidine in Anesthesia and Intensive Care: A Review
Current Pharmaceutical Design Drug-Like Inhibitors of Protein-Protein Interactions: A Structural Examination of Effective Protein Mimicry
Current Protein & Peptide Science Three Musketeers for Lowering Cholesterol: Statins, Ezetimibe and Evolocumab
Current Medicinal Chemistry The Role of Drug Transporters in the Pharmacokinetics of Antibiotics
Current Drug Metabolism Nanotechnology for Delivery of Drugs and Biomedical Applications
Current Clinical Pharmacology Preoperative and Follow up Multi-Detector Row CT Angiography (MDCTA) in the Evaluation of Interrupted Aortic Arch (IAA)
Current Medical Imaging Metabolic Programming Nowadays (or Perhaps Now and then?)
Current Nutrition & Food Science Atheroma Burden and Morphology in Women
Current Pharmaceutical Design Chagas Disease: Progress and New Perspectives
Current Medicinal Chemistry Isotyping the Human TOMM40 Variable-Length Polymorphism by Gene Amplification and Restriction Digest
Current Alzheimer Research Patent Selections
Recent Patents on Cardiovascular Drug Discovery